S

Shenzhen Salubris Pharmaceuticals Co Ltd
SZSE:002294

Watchlist Manager
Shenzhen Salubris Pharmaceuticals Co Ltd
SZSE:002294
Watchlist
Price: 31.74 CNY -1.64%
Market Cap: 35.4B CNY
Have any thoughts about
Shenzhen Salubris Pharmaceuticals Co Ltd?
Write Note

EV/EBITDA
Enterprise Value to EBITDA

52.5
Current
55
Median
13.5
Industry
Lower than median
Higher than industry value

Enterprise Value to EBITDA (EV/EBITDA) ratio is a valuation multiple that compares the value of a company, debt included, to the company’s cash earnings less non-cash expenses. EBITDA can be misleading at times, especially for companies that are highly capital intensive.

EV/EBITDA
52.5
=
Enterprise Value
32.5B CNY
/
EBITDA
619.9m CNY
All Countries
Close

EV/EBITDA Forward Multiples

Forward EV/EBITDA multiple is a version of the EV/EBITDA ratio that uses forecasted EBITDA for the EV/EBITDA calculation. 1-Year, 2-Years, and 3-Years forwards use EBITDA forecasts for 1, 2, and 3 years ahead, respectively.

1-Year Forward
EV/EBITDA
31.7
2-Years Forward
EV/EBITDA
29
3-Years Forward
EV/EBITDA
25.3

See Also

Discover More